THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Mohamad Khawandanah and Sami Ibrahimi.
Mohamad Khawandanah
Connection Strength
0.317
Sami Ibrahimi
  1. Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA). Hematol Oncol Stem Cell Ther. 2018 Sep; 11(3):187-188.
    View in: PubMed
    Score: 0.154
  2. Impact of primary organ site of involvement by peripheral T-cell lymphoma not otherwise specified on survival. Cancer Med. 2023 Dec 11.
    View in: PubMed
    Score: 0.058
  3. Impact of Race and Age and their Interaction on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2023 05; 23(5):379-384.
    View in: PubMed
    Score: 0.054
  4. Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. Bone Marrow Transplant. 2022 06; 57(6):1025-1027.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES